INKT Stock — MiNK Therapeutics, Inc.

Up next

Next earnings call

Feb 9, 2027 Est · unconfirmed · in 12 wks

Q2 2026 earnings call transcript

call held Aug 13, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 12

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Cash at $7.5 million amid going-concern uncertainty

MiNK Therapeutics reported $7.5 million in cash as of September 30, 2026 and substantial doubt about its ability to continue as a going concern; it also recognized first pre-commercial agenT-797 revenue of approximately $0.2 million.

Revenue $200K Net loss $2.55M Diluted EPS -$0.50

Read from the MD&A section

3 source passages

Our cash and cash equivalents balance as of September 30, 2026 was $7.5 million. Because the completion of anticipated funding is not entirely within our control, we are required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. During the three months ended September 30, 2026, we recognized our first pre-commercial product revenue of approximately $0.2 million from agenT-797 supplied under the program. Open the document at this passage

Nov 12

Current report 8-K

First pre-commercial revenue as ARDS trial advances

MiNK Therapeutics reported $0.2 million in first pre-commercial product revenue from agenT-797, while its randomized Phase 2 ARDS trial continued enrolling, with U.S. dosing expected before year-end 2026 and data expected 2H2027.

Financial results

4 source passages

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies, reported financial results for the third quarter ended September 30, 2026, and highlighted a quarter in which agenT-797 realized pre-commercial revenue, its randomized trial in acute respiratory distress syndrome (ARDS) is advancing , and an ARPA-H program selected the Company’s cells to generate living medicines can be delivered without a freezer. The Company recognized $0.2 million in pre-commercial product revenue – its first – from agenT-797 supplied through the named-patient access program. MiNK’s randomized, placebo-controlled Phase 2 study of agenT-797 plus standard of care in adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure (C-1300-02) continued enrolling in Lviv, Ukraine during the quarter. U.S. dosing is expected before year-end, with data expected 2H2027. Activate U.S. ICU sites and begin U.S. dosing in C-1300-02 before year-end 2026; sustain enrollment Open the document at this passage

Aug 13

Earnings call

Q2 2026 earnings call AI summary on its way

Aug 13

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Net loss $3.13M Diluted EPS -$0.62

Aug 13

Current report 8-K

Financial results AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$11.02M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$7.47M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+14.8%

Year over year · more shares

Price change (1Y)

-29.3%

Trailing year

Short interest

1.1%

Latest settlement · 4.3 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

· $0 −$2.89M '25 Q3 LATEST · $200,000 −$2.55M '26 Q3

AI Brief

Q2 FY26 earnings call · Aug 13, 2026

Q2 FY26

TL;DR. MiNK Therapeutics advanced agenT-797 into the randomized portion of its Phase 2 study C-1300-02 in ARDS/acute lung injury, reported initial Day 28 observations showing survival and clinical improvements, and established its first paid international named-patient access program in Brazil, while narrowing its quarterly net loss.

Bullish

+ Initiated dosing in the randomized Phase 2 trial C-1300-02 of agenT-797 in acute lung injury/ARDS under an active U.S. IND.
+ Established the company's first paid international named-patient access program in Brazil, supplying agenT-797 on a per-patient paid basis.
+ Quarterly net loss narrowed to $3.1 million ($0.62/share) from $4.2 million ($1.06/share) year over year, with six-month net loss narrowing to $5.9 million from $7.0 million.

Bearish

− Cash and cash equivalents declined to $8.8 million as of June 30, 2026 from $13.4 million at year-end 2025.
− Cash used in operations increased to $2.1 million in Q2 2026 from $1.6 million a year ago, reflecting deliberate Phase 2 launch costs.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −17%

below

Price vs 50-day avg −16%

below

RSI (14) 36

neutral

MACD trend Negative

52-week position 14%

near low

Momentum

relative strength

Very Weak

1-month return −1%

trailing

6-month return −11%

trailing

YTD return −16%

this year

Relative strength −11%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $11 › 200d $11 — 200d above 50d

Institutional flow Distributing

25 of 29 funds reported for Sep 30 · net -7.6K sh shares

Insider flow Distributing

Net -$73.3K over 90 days · 100% sells

Short interest Rising

1.07% of shares out · ▲ +15.3% MoM · 4.3 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

29 holders — mid 3-yr range

Squeeze score 58

elevated · 0–100

Fundamentals

Poor

EPS growth −2%

Y/Y

Free cash flow $-6.0M

Quant / Vol

risk profile

Very High

Volatility 73%

annualized · 1-yr

Max drawdown −37%

past year

ATR 7.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 2 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−17% Bearish

Price vs 50-day avg

−16% Bearish

RSI (14)

36 Neutral

MACD trend

Negative Bearish

52-week position

14% Bearish

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $11 › 200d $11 — 200d above 50d

Institutional flow Distributing

25 of 29 funds reported for Sep 30 · net -7.6K sh shares

Insider flow Distributing

Net -$73.3K over 90 days · 100% sells

Short interest Rising

1.07% of shares out · ▲ +15.3% MoM · 4.3 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

29 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $9 Now $9 · 14% Range high $14

vs 200-day avg -17% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INKT MiNK Therapeutics, Inc. this stock	$47.95M	-16.2%	—	—	1.1%
VRTX Vertex Pharmaceuticals Inc	$136.56B	+18.8%	+46.2%	34.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.84B	+23.8%	+20.8%	21.1	2.1%
MRNA Moderna, Inc.	$90.38B	+657.4%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.05B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

26

% held: 4.1%
Reported: 25 of 29
Top holder: VANGUARD CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

10

View

Short & Settlement

Short Interest Rising

Shares short

55.1K

Days to cover: 4.3d
Change: +7.3K sh

View

Short Volume

Short vol %

66%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

1.0K

Value: $11.1K
As of: Oct 9, 2026

View

Off-Exchange

Off-exchange %

51.7%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$73.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-12.5M

EPS diluted: $-2.93

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 12, 2026
This year: 15

MiNK Therapeutics reported $7.5 million in cash as of September 30, 2026 and substantial doubt about its ability to continue as a going concern; it also recognized first pre-commercial agenT-797 revenue of approximately $0.2 million.

View

Proposed Sales

Value

$73.3K

Shares: 6.9K
Filed: Oct 13, 2026

View

Earnings & Events

Webcasts

Last webcast

Nov 11, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
INKT	-9.8%	-0.7%	-10.5%	-11.3%	-16.2%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-12.4%	+0.4%	-11.0%	-11.1%	-26.9%

INKT · MiNK Therapeutics, Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance